Day 2 Program

Rapid Fire 4

Day 2: December 9, 2026

5:30 PM–6:30 PM CST

Stars at Night 1-2

Session Details

Moderator

Christos Vaklavas

Moderator

Shaheenah Dawood

RF4-1

Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for High-Risk, Early-Stage Triple-Negative Breast Cancer (TNBC): Final Analysis Results in the T2N0 Subgroup From the Phase 3 KEYNOTE-522 Study

Peter Schmid, Barts Cancer Institute, Queen Mary University London, London, United Kingdom

RF4-2

Long-term outcomes after pathological complete response (pCR) to neoadjuvant chemo-immunotherapy (NA-CIO) without adjuvant PD-1/PD-L1 inhibition in early-stage triple negative breast cancer: an individual patient pooled analysis

Stephen J Luen, Peter MacCallum Cancer Centre, Melbourne, Australia

RF4-4

Efficacy and safety of bulumtatug fuvedotin (BFv, 9MW2821), a Nectin-4 antibody-drug conjugate (ADC), in patients with advanced triple-negative breast cancer (aTNBC) previously treated with antibody-drug conjugates (ADCs): a phase Ib dose optimization study (9MW2821-CP103).

Nour Abuhadra, Memorial Sloan Kettering Cancer Center, New York, NY

RF4-3

Whole-genome sequencing-defined homologous recombination deficiency predicts carboplatin benefit in early triple-negative breast cancer: long-term survival outcome and biomarker analysis of the phase III PEARLY trial (KCSG BR 15-1)

Joohyuk Sohn, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of

RF4-5

Phase II Study of Izalontamab Brengitecan (iza-bren) Combined with Toripalimab in Patients with Unresectable Locally Advanced, Recurrent or Metastatic Triple-Negative Breast Cancer (TNBC)

Jian Zhang, Fudan University Shanghai Cancer Center, Shanghai, China

RF4-6

Safety and preliminary efficacy of SYS6010 monotherapy in patients with HER2-negative, EGFR-expressing breast cancer

Jian Zhang, Fudan University Shanghai Cancer Center, Shanghai, China